Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 2
1956 1
1961 2
1962 3
1963 1
1964 9
1965 1
1966 2
1967 5
1968 7
1969 8
1970 6
1971 9
1972 13
1973 6
1974 9
1975 6
1976 11
1977 8
1978 14
1979 12
1980 22
1981 16
1982 20
1983 31
1984 27
1985 38
1986 43
1987 46
1988 48
1989 63
1990 64
1991 50
1992 74
1993 48
1994 67
1995 63
1996 77
1997 85
1998 92
1999 87
2000 84
2001 73
2002 58
2003 70
2004 98
2005 99
2006 106
2007 91
2008 89
2009 87
2010 99
2011 121
2012 119
2013 145
2014 143
2015 123
2016 137
2017 144
2018 145
2019 131
2020 173
2021 200
2022 229
2023 190
2024 42

Text availability

Article attribute

Article type

Publication date

Search Results

3,902 results

Results by year

Filters applied: . Clear all
Page 1
Cefepime-induced neurotoxicity: systematic review.
Maan G, Keitoku K, Kimura N, Sawada H, Pham A, Yeo J, Hagiya H, Nishimura Y. Maan G, et al. Among authors: nishimura y. J Antimicrob Chemother. 2022 Oct 28;77(11):2908-2921. doi: 10.1093/jac/dkac271. J Antimicrob Chemother. 2022. PMID: 35971666
Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial.
Kiyota N, Tahara M, Mizusawa J, Kodaira T, Fujii H, Yamazaki T, Mitani H, Iwae S, Fujimoto Y, Onozawa Y, Hanai N, Ogawa T, Hara H, Monden N, Shimura E, Minami S, Fujii T, Tanaka K, Homma A, Yoshimoto S, Oridate N, Omori K, Ueda T, Okami K, Ota I, Shiga K, Sugasawa M, Asakage T, Saito Y, Murono S, Nishimura Y, Nakamura K, Hayashi R; Head and Neck Cancer Study Group of the Japan Clinical Oncology Group (JCOG-HNCSG). Kiyota N, et al. Among authors: nishimura y. J Clin Oncol. 2022 Jun 20;40(18):1980-1990. doi: 10.1200/JCO.21.01293. Epub 2022 Mar 1. J Clin Oncol. 2022. PMID: 35230884 Free PMC article. Clinical Trial.
Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL.
Miyazaki K, Sakai R, Iwaki N, Yamamoto G, Murayama K, Nishikori M, Sunami K, Yoshida I, Yano H, Takahashi N, Okamoto A, Munemoto S, Sawazaki A, Suehiro Y, Fukuhara N, Wake A, Arai A, Masaki Y, Toyama K, Yokoyama A, Tsunemine H, Hasegawa Y, Matsumoto K, Yamada T, Nishimura Y, Tamaru S, Asano N, Miyawaki K, Izutsu K, Kinoshita T, Suzuki R, Ohshima K, Kato K, Katayama N, Yamaguchi M. Miyazaki K, et al. Among authors: nishimura y. Cancer Sci. 2023 Jun;114(6):2689-2691. doi: 10.1111/cas.15784. Epub 2023 Mar 16. Cancer Sci. 2023. PMID: 36929591 Free PMC article. Clinical Trial. No abstract available.
[Preface].
Nishimura Y, Tomita S. Nishimura Y, et al. Nihon Yakurigaku Zasshi. 2023;158(6):427. doi: 10.1254/fpj.23070. Nihon Yakurigaku Zasshi. 2023. PMID: 37914315 Japanese. No abstract available.
Validation of a New Methodology to Create Oral Drugs beyond the Rule of 5 for Intracellular Tough Targets.
Ohta A, Tanada M, Shinohara S, Morita Y, Nakano K, Yamagishi Y, Takano R, Kariyuki S, Iida T, Matsuo A, Ozeki K, Emura T, Sakurai Y, Takano K, Higashida A, Kojima M, Muraoka T, Takeyama R, Kato T, Kimura K, Ogawa K, Ohara K, Tanaka S, Kikuchi Y, Hisada N, Hayashi R, Nishimura Y, Nomura K, Tachibana T, Irie M, Kawada H, Torizawa T, Murao N, Kotake T, Tanaka M, Ishikawa S, Miyake T, Tamiya M, Arai M, Chiyoda A, Akai S, Sase H, Kuramoto S, Ito T, Shiraishi T, Kojima T, Iikura H. Ohta A, et al. Among authors: nishimura y. J Am Chem Soc. 2023 Nov 8;145(44):24035-24051. doi: 10.1021/jacs.3c07145. Epub 2023 Oct 24. J Am Chem Soc. 2023. PMID: 37874670
Use of R-mini-CHP in combination with polatuzumab vedotin (pola-R-mini-CHP) as the primary treatment in ≥80-year-old cases with diffuse large B-cell lymphoma.
Sekiguchi Y, Tsutsumi H, Gomyo A, Kudo M, Iizaki Y, Maseki N, Kawamura M, Kobayashi K, Nishimura Y, Kanda H, Nitta H, Noguchi M, Kobayashi H. Sekiguchi Y, et al. Among authors: nishimura y. J Clin Exp Hematop. 2023;63(4):262-265. doi: 10.3960/jslrt.23043. J Clin Exp Hematop. 2023. PMID: 38148017 Free PMC article. No abstract available.
Editorial: Endoscopic spine surgery.
Yu Y, Li ZZ, Nishimura Y. Yu Y, et al. Among authors: nishimura y. Front Surg. 2023 Jan 9;9:1127851. doi: 10.3389/fsurg.2022.1127851. eCollection 2022. Front Surg. 2023. PMID: 36700034 Free PMC article. No abstract available.
Development of Orally Bioavailable Peptides Targeting an Intracellular Protein: From a Hit to a Clinical KRAS Inhibitor.
Tanada M, Tamiya M, Matsuo A, Chiyoda A, Takano K, Ito T, Irie M, Kotake T, Takeyama R, Kawada H, Hayashi R, Ishikawa S, Nomura K, Furuichi N, Morita Y, Kage M, Hashimoto S, Nii K, Sase H, Ohara K, Ohta A, Kuramoto S, Nishimura Y, Iikura H, Shiraishi T. Tanada M, et al. Among authors: nishimura y. J Am Chem Soc. 2023 Aug 2;145(30):16610-16620. doi: 10.1021/jacs.3c03886. Epub 2023 Jul 18. J Am Chem Soc. 2023. PMID: 37463267
Technology using simulated microgravity.
Nishimura Y. Nishimura Y. Regen Ther. 2023 Aug 22;24:318-323. doi: 10.1016/j.reth.2023.08.001. eCollection 2023 Dec. Regen Ther. 2023. PMID: 37662695 Free PMC article. Review.
Editorial: Primary cilia as therapeutic targets.
Nishimura Y, Saito M, Otsu W, Miyadera K. Nishimura Y, et al. Front Mol Biosci. 2023 Oct 26;10:1322873. doi: 10.3389/fmolb.2023.1322873. eCollection 2023. Front Mol Biosci. 2023. PMID: 37965380 Free PMC article. No abstract available.
3,902 results